Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0042251084
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BHG9K0
ACAD
ACADIA Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ACADIA Pharmaceuticals Inc
ISIN
US0042251084
TICKER
ACAD
MIC
XNAS
REUTERS
ACAD.OQ
BLOOMBERG
ACAD US
Thu, 29.05.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and a...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia’s commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.05.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 64,252 shares of common stock and 56,277 restricted stock units (“RSUs”) to twenty-eight new employees under Acad...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.05.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s order, the Court ruled in favor of Acadia on both infringement...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter,” said Catherine Owen Adams, Chief Executive Officer. “DAYBUE has achieved meaningful patient growth for the first ti...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.05.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 3:40 p.m. Pacific Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.04.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia’s website,...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.04.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Aca...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.03.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.03.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 05.03.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar s...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.03.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers. In the study, ACP-711 was safe and generally well tolerated across al...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.02.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archiv...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.02.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025,” said Catherine Owen Adams, Chief Executive Offic...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.02.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 171,065 shares of common stock and 55,170 restricted stock units (“RSUs”) to eighteen new employees under Ac...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.02.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time. The webcast will...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,782 shares of common stock and 13,928 restricted stock units (“RSUs”) to twelve new employees under Acadi...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.01.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2025 is shaping...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.01.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the firs...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.12.2024       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring Independent Bank Group in a deal expected...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 19.12.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcas...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.12.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units (“RSUs”) to thirteen new employees under Aca...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.12.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net pro...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.12.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.11.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.11.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eas...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.11.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.11.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. “The success of Acadia’s two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive mileston...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.11.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of D...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.10.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operation...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.10.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority Review process. The Notice of Compliance authorization of DAYBUE makes it the first and only drug...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.10.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,631 shares of common stock and 30,484 restricted stock units (“RSUs”) to thirteen new employees under Aca...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.09.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia’s new Chief Executive Officer, a one-time sign-on equity award of (i) 353,261 options to purchase shares of Acadia’s common stock with an exercise price of $16.29 per share, Acadia’s closing trading pri...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.09.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. “We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. “Catherine is a prov...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.08.2024       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.08.2024       ACADIA Pharmaceuticals
US0042251084

Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Pa...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.03.2024       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - March 27, 2024) - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. ("Acadia " or "the Company") (NASDAQ: ACAD). Investors who purchased Acadia securities prior to September 9, 2019, and continue to hold to the present, are encouraged...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.03.2024       ACADIA Pharmaceuticals
US0042251084

Philadelphia, Pennsylvania--(Newsfile Corp. - March 19, 2024) - Attention long-term investors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD): A federal securities fraud complaint that filed on behalf of shareholders of Acadia Pharmaceuticals was recently certified as a class action. That complaint alleges that Acadia, via certain officers and direc...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.03.2024       ACADIA Pharmaceuticals
US0042251084

Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2024) - A federal securities fraud complaint filed on behalf of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors was recently certified as a class action. That complaint alleges that Acadia, via certain officers and directors, made materially false and misleading statements regarding the...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.03.2024       ACADIA Pharmaceuticals
US0042251084

Los Angeles, California--(Newsfile Corp. - March 13, 2024) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of the securities laws.The investigation focuses on whether the Com...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.03.2024       ACADIA Pharmaceuticals
US0042251084

Los Angeles, California--(Newsfile Corp. - March 12, 2024) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of the securities laws.The investigation focuses on whether the Com...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.03.2024       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - March 5, 2024) - Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether ACADIA and certai...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.02.2024       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - February 26, 2024) - Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether ACADIA and ce...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.07.2022       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) ("Acadia" or the "Company") and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed unde...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.06.2021       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class acti...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.06.2021       ACADIA Pharmaceuticals
US0042251084

Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 19.06.2021       ACADIA Pharmaceuticals
US0042251084

San Francisco, California--(Newsfile Corp. - June 19, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 21, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com84...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.06.2021       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - June 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class actio...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.06.2021       ACADIA Pharmaceuticals
US0042251084

Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.06.2021       ACADIA Pharmaceuticals
US0042251084

New York, New York--(Newsfile Corp. - June 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities betwee...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink